Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

NCT ID: NCT05377216

Last Updated: 2025-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-01

Study Completion Date

2027-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventricular Tachycardia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stellate ganglion block

All subjects will undergo stellate ganglion block during their VT ablation procedure

Group Type EXPERIMENTAL

Stellate Ganglion Block

Intervention Type DRUG

Left sided percutaneous stellate ganglion block

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stellate Ganglion Block

Left sided percutaneous stellate ganglion block

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Planned catheter based VT ablation
* Age at least 18 years

Exclusion Criteria

* Pregnancy
* Contraindication to SGB or VT ablation
* Hypersensitivity of local anesthetic of amide type
* Hemodynamic instability during the procedure prior to the study protocol
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Timothy Markman, MD

Role: CONTACT

267-593-0103

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Timothy Markman, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

851066

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.